EFFECT OF CHOLESTEROL-LOWERING DIET ON MORTALITY FROM CORONARY HEART-DISEASE AND OTHER CAUSES: A Twelve-year Clinical Trial in Men and Women

doi:10.1016/S0140-6736(72)92208-8

The Lancet

Volume 300, Issue 7782, 21 October 1972, Pages 835-838

https://doi.org/10.1016/S0140-6736(72)92208-8 Get rights and content

Abstract

The mortality from coronary heart-disease (C.H.D.) and other causes was studied in two mental hospitals during a long-term (twelve-year) controlled preventive trial. The trial was cross-over in design. In one of the hospitals a serum-cholesterol-lowering diet was introduced and the other hospital using a normal diet served as the control. After six years the diets were reversed, and the trial was continued for six more years. In men, the use of the cholesterol-lowering diet was associated with considerably and significantly reduced mortality from C.H.D. Total mortality also was consistently lower on this diet, although the differences were too small for statistical significance. In women, the mortality from C.H.D. also appeared to be lower during the diet period, but the differences were small and not significant. In female total mortality no appreciable differences were found.

References (14)

O. Turpeinen et al.
Am. J. clin. Nutr.
(1968)
J. Hirsch et al.
Am. J. clin. Nutr.
(1960)
L.L. Abell et al.
F. Ederer et al.
Lancet
(1971)
G. Christakis et al.
Am. J. publ. Hlth
(1966)
S. Dayton et al.
Circulation
(1969)

There are more references available in the full text version of this article.

Cited by (322)

The Effect of Raloxifene Treatment on Lipid Profile in Elderly Individuals: A Systematic Review and Meta-analysis of Randomized Clinical Trials
2021, Clinical Therapeutics
To perform a systematic review and meta-analysis of randomized clinical trials (RCTs) to elucidate the effects of raloxifene on the lipid profile in elderly individuals.
A systematic review and meta-analysis of RCTs was performed following the PRISMA statement. Data on triglycerides (TGs), total cholesterol (TC), HDL-C, and LDL-C were extracted. Relevant publications up to October 2020 were detected through searches in the PubMed/MEDLINE, Web of Science, Scopus, and Embase databases. Changes were reported as weighted mean differences (WMDs) and 95% CIs using random-effects models.
Nine studies were selected, with a duration of intervention ranging from 2 and 12 months and a raloxifene dose of 60 to 120 mg/d. Studies were performed in healthy individuals and in those with disorders, such as osteoporosis, type 2 diabetes, and kidney disease required long-term hemodialysis. Overall, TG (WMD, −6.50 mg/dL; 95% CI, −34.18 to 21.20 mg/eL; P = 0.646), LDL-C (WMD, −17.86 mg/dL; 95% CI, −42.44 to 6.72 mg/dL; P = 0.154), and HDL-C (WMD, 2.35 mg/dL; 95% CI, −1.14 to 5.84 mg/dL; P = 0.187) levels did not change significantly after the administration of raloxifene. In contrast, TC levels decreased after raloxifene therapy (WMD, −6.59 mg/dL; 95% CI, −13.13 to −0.05 mg/dL; P = 0.048).
Raloxifene therapy decreased TC levels but did not alter TG, HDL-C, and LDL-C concentrations in elderly individuals. Regarding the LDL-C levels, although the finding lacked statistical significance, we believe that there was a mean reduction that deserves further clinical attention as much as TC.
Does variation in serum LDL-cholesterol response to dietary fatty acids help explain the controversy over fat quality and cardiovascular disease risk?
2021, Atherosclerosis
Citation Excerpt :
These findings were later supported by the outcome of epidemiological studies of Ancel Keys [20,21], which laid the foundation for the ‘diet-heart hypothesis’ and earliest guideline to reduce intake of total fat and SFA to prevent heart attacks in the USA in 1961 [22]. Further evidence for the efficacy for this hypothesis would follow from randomised intervention trials (RCT) [23–25], and the most comprehensive meta-analysis to date of RCTs, that showed a 27% reduction in cardiovascular events in response to the replacement of SFA with polyunsaturated fat [26]. A fundamental principle that distinguishes the relatively subtle physiological effects of diet from the pharmacological effects of drugs, is the obligation to replace a removed macronutrient with a substitute macronutrient to render the diet viable.
Controversy over fat quality and cardiovascular disease risk stems from a series of meta-analyses of prospective cohort and randomised intervention trials, which found little evidence for a significant relationship between the intake of saturated fat and disease endpoints. Possible explanations for these null findings include difficulties inherent in estimating true food intake, the confounding effects of macronutrient replacement and food composition, and marked inter-individual variation in the response of serum LDL-cholesterol. The aim of this narrative review was to present evidence for the existence and origins of variation in serum LDL-cholesterol response to the replacement of dietary saturated fat, and its potential to explain the controversy over the latter. The review provides evidence to suggest that variation in LDL-responsiveness may harbour significant potential to confound the relationship between saturated fat and atherosclerotic cardiovascular disease risk, thus undermining the effectiveness of the dietary guideline to replace saturated fat with unsaturated fat. It concludes that the identification and application of a simple biomarker of this phenomenon, would make it possible to tailor dietary guidelines to LDL responsive individuals, who stand to gain a greater benefit to their cardiovascular health.
Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now
2019, Canadian Journal of Cardiology
Citation Excerpt :
Clinical trials of cholesterol-lowering from that era were never definitive, mainly because none of the available treatments were safe and effective at lowering low-density lipoprotein cholesterol (LDL-C). The most interesting part of these trials from the modern perspective is the high levels of baseline cholesterol; mean total cholesterol in primary prevention trials of various diets ranged from 6.0 to 7.0 mmol/L and in secondary prevention, from 6.5 to 8.3 mmol/L.10-16 In none of these studies were baseline cholesterol levels used to select patients; these were the usual adult cholesterol levels of that era. During 2011-2014, mean serum total cholesterol level for United States (U.S.) adults averaged 5.0 mmol/L,17 and for Canadian adults, 5.1 mmol/L.18 A gradual decline in cholesterol levels in adults has occurred over the past 50 years in most Western countries, and over the past 20 years this trend has accelerated with increasingly widespread statin use.
Treatment guidelines have proliferated in cardiology, although most guideline recommendations are not supported by clinical trial evidence. What is considered to be a normal cholesterol level has progressively declined over the past 50 years, with the increasing realization that “normal” is far from optimal and that lower is better. The first important United States and Canadian cholesterol guidelines were published in 1988, and recommended diet for 6 months to be followed by consideration of bile acid sequestrants or nicotinic acid. Over the ensuing 25 years guidelines have changed rapidly and dramatically in response to a large number of definitive clinical trials, usually with statins. Low-density lipoprotein cholesterol targets have moved progressively lower, and in some guidelines, have been abandoned entirely. The concept of selecting patients for treatment according to the absolute risk reduction expected from treatment on the basis of clinical trial data seems to be a rational approach. For secondary prevention, some patients are still untreated or undertreated, presenting an opportunity for improving outcomes.
Les lignes directrices sur les traitements se sont multipliées en cardiologie, mais la plupart des recommandations qu’elles contiennent ne sont pas appuyées par des données probantes recueillies dans le cadre d’essais cliniques. La valeur considérée comme un taux de cholestérol normal a diminué progressivement au cours des 50 dernières années, alors que l’on réalisait de plus en plus que la valeur « normale » était loin d’être optimale et qu’il était préférable de l’abaisser encore. Les premières lignes directrices importantes sur le cholestérol aux États-Unis et au Canada ont été publiées en 1988 et préconisaient un régime alimentaire pendant 6 mois suivi d’un traitement éventuel par des chélateurs des acides biliaires ou par l’acide nicotinique. Au cours des 25 années suivantes, la teneur des lignes directrices a changé de façon rapide et radicale en réponse aux résultats de plusieurs essais cliniques déterminants, portant en général sur les statines. Les cibles de cholestérol à lipoprotéines de basse densité ont vu leur importance diminuer progressivement, jusqu’à être totalement abandonnées dans certaines lignes directrices. Le concept de sélection des patients à traiter reposant sur la réduction du risque absolu attendue du traitement en se fondant sur les résultats des essais cliniques semble être une approche rationnelle. Pour ce qui est de la prévention secondaire, il existe une possibilité d’améliorer l’évolution de l’état de santé des patients puisque certains demeurent encore non traités ou sous-traités.
Dietary n-6 polyunsaturated fatty acids and cardiovascular disease: Epidemiologic evidence
2018, Prostaglandins Leukotrienes and Essential Fatty Acids
Citation Excerpt :
For example, most of the participants assigned to the low-fat diet were unable to achieve their fat reduction target of 20% in the WHI Dietary Modification Trial [42]. Examples of RCTs with high compliance include two studies conducted many decades ago, the Finnish Mental Hospital Study and the Wadsworth Hospital and Veterans Administration Center Study [43–46]. The two trials achieved strict dietary control and therefore large between-group difference in LA intake.
Epidemiologists have been studying the effect of n-6 polyunsaturated fatty acids (PUFAs) intake on the risk of cardiovascular disease (CVD) for many decades. Abundant evidence from prospective studies on the clinical endpoints of CVD, including cohort studies measuring n-6 PUFA intake by food frequency questionnaires and nested case-control studies using biomarkers of intake level, strongly support that higher intakes of n-6 PUFAs are associated with a lower risk of CVD. Furthermore, a significant reduction in CVD risk can be achieved when saturated fatty acids (SFAs) is replaced by n-6 PUFAs. Evidence from appropriately designed and vigorously executed randomized controlled trials support that high-PUFA (predominantly linoleic acid) and low-SFA diets, compared to high-SFA diets, reduced the risk of coronary heart disease. Overall, epidemiologic studies provide a solid evidence base of the current dietary guidelines that recommend replacing SFA by PUFA, both n-6 and n-3 PUFA, for CVD prevention.
Targeting LDL: Is lower better and is it safe?
2014, Best Practice and Research: Clinical Endocrinology and Metabolism
Citation Excerpt :
These early epidemiological associations with cancer were subsequently reinforced by cholesterol reducing interventions in the late 1970s when trials such as the WHO clofibrate primary prevention trial reported a statistically significant (p < 0.05) increase in cancer deaths, along with increased other non cardiac deaths associated with clofibrate treatment [54]. It was noted that prior cholesterol lowering trials with diet, mostly enriched with polyunsaturated fats, had also reported excess mortality, even if not statistically significant [55,56]. The relationship between pharmacological reduction and cancer was re-ignited with the pravastatin CARE trial which reported an increased incidence of breast cancer in women in patients treated with pravastatin [13].
Low density lipoprotein cholesterol (LDL-C) is one of the most validated targets in clinical medicine. Large randomized, outcome trials have demonstrated a clear relationship between reducing LDL-C and cardiovascular disease (CVD) risk, which has been maintained to LDL-C levels of <1.8 mmol/L. To assess the benefit of even lower LDL-C it is important to recognize that CVD risk reduction is related to absolute reduction in LDL-C, not to percent change. Furthermore measurement of LDL-C is also critical as recent studies show the Friedewald calculation significantly underestimates true LDL-C values <1.8 mmol/L, distorting the relationship with CVD risk reduction.
Discussion of potential harm from low, or lower, LDL-C has centered on cancer, hemorrhagic stroke, and violent death, but there is little evidence from outcome trials to show a relationship with low LDL-C. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors which will reduce LDL-C well below 1.3 mmol/L, will likely provide the clearest answer to both the question of efficacy and safety of low LDL-C within the next few years.
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia - Full report
2014, Journal of Clinical Lipidology
An international panel of the International Atherosclerosis Society has developed a new set of recommendations for the management of dyslipidemia. The panel identifies non-high-density lipoprotein cholesterol as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic lipoproteins; drug therapy is reserved for subjects at greater risk. Risk assessment is based on estimation of lifetime risk according to differences in baseline population risk in different nations or regions. Secondary prevention emphasizes use of cholesterol-lowering drugs to attain optimal levels of atherogenic lipoproteins.

View all citing articles on Scopus

View full text

EFFECT OF CHOLESTEROL-LOWERING DIET ON MORTALITY FROM CORONARY HEART-DISEASE AND OTHER CAUSES: A Twelve-year Clinical Trial in Men and Women

Abstract

Am. J. clin. Nutr.

Am. J. clin. Nutr.

Lancet

Am. J. publ. Hlth

Circulation